Itamar Medical Ltd. (ITMR)
| Market Cap | 361.79M |
| Revenue (ttm) | 31.26M |
| Net Income (ttm) | -5.27M |
| Shares Out | 287.62M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $25.23 |
| Previous Close | $25.50 |
| Change ($) | -0.27 |
| Change (%) | -1.06% |
| Day's Open | 25.35 |
| Day's Range | 24.94 - 25.49 |
| Day's Volume | 16,732 |
| 52-Week Range | 7.95 - 29.00 |
CAESAREA, Israel, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea m...
CAESAREA, Israel, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea m...
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from He...
WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in conversion rates WatchPAT™ to effectively maintain current reimbursement levels despite broader redu...
Results Further Support Use of WatchPAT for Home-Based Sleep Apnea Testing as an Effective Alternative to In-Lab PSG Testing Results Further Support Use of WatchPAT for Home-Based Sleep Apnea ...
CAESAREA, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercializatio...
Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q3 2020 Results - Earnings Call Transcript
Initial findings show potential for material short-term annual savings of up to $5,000 per cardiovascular patient when treated for sleep apnea Initial findings show potential for material shor...
- Third Quarter Revenues Increase 36 % to $ 11.0 Million -
CAESAREA, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasi...
CAESAREA, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and...
Q3 Total Revenue Results of $10.7 M to $ 11 . 0 M , reflecting growth of 32 %- 36 %
CAESAREA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and...
Updated guidelines represent a significant milestone in the adoption of Itamar’s Peripheral Arterial Tonometry (PAT) based Home Sleep Apnea Testing (HSAT) in Europe, following adoption in the ...
CAESAREA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercializa...
CAESAREA, Israel, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercializat...
As a platinum sponsor, Itamar Medical’s virtual booth and on-demand content to be offered to SLEEP 2020 attendees As a platinum sponsor, Itamar Medical’s virtual booth and on-demand content to...
Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q2 2020 Results - Earnings Call Transcript
Itamar Medical Ltd. Sponsored ADR (ITMR) delivered earnings and revenue surprises of 10.53% and 12.18%, respectively, for the quarter ended June 2020.
Itamar Medical Ltd. Sponsored ADR (ITMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAESAREA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-inva...
Itamar Medical (ITMR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Itamar Medical Ltd. Sponsored ADR (ITMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
As of late, it has definitely been a great time to be an investor in Itamar Medical.
- First Quarter 2020 Revenues Increase 38% to $8.4 Million -
Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies Complete, home-based solution for diagnosing res...
Study conducted at Mount Sinai Hospital in New York City designed to demonstrate benefit of continuous positive airway pressure (CPAP) in delaying or eliminating hospitalization and/or ventila...
- Company Ramping Up WatchPAT™ ONE Production Capacity to Meet Demand for Disposable Home Sleep Apnea Tests -
Streamlining the complex process from sleep apnea diagnosis to treatment using digital health platforms meets shared mission of addressing the growing and undermanaged sleep apnea epidemic
CAESAREA, Israel, March 20, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-in...
Study will evaluate how raw signals from tens of thousands of WatchPAT recordings conducted over the last 10 years in combination with health medical records can be leveraged to predict cardio...
Two additional published studies highlight WatchPAT’s accuracy and effectiveness in patients with Central Sleep Apnea (CSA) and Chronic Obstructive Pulmonary Disease (COPD)
CAESAREA, Israel, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-inva...
CAESAREA, Israel, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-inva...
CAESAREA, Israel, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-inva...
- 2019 Fiscal Year Revenues Expected to Increase 29% to $31.1 Million to $31.3 Million -
Selection of Itamar's WatchPAT home sleep apnea diagnostic system underscores the importance and significance of understanding sleep disorders to prevent and manage risk of heart disease and s...
About ITMR
Itamar Medical engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enables home sleep tests for various sleeping disorders, including obstructive sleep apnea; and Endo PAT device that diagnoses endothelial dysfunction. The company operat... [Read more...]
| Industry Medical Devices | Founded 1997 |
| CEO Gilad Glick | Employees 184 |
| Stock Exchange NASDAQ | Ticker Symbol ITMR |
Financial Performance
In 2019, Itamar Medical's revenue was $31.26 million, an increase of 29.22% compared to the previous year's $24.19 million. Losses were -$5.27 million, 204.7% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for Itamar Medical stock is "Strong Buy." The 12-month stock price forecast is 28.66, which is an increase of 13.59% from the latest price.